Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Mar 17;231(3):e478-e487.
doi: 10.1093/infdis/jiae581.

A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants

Shabir A Madhi  1 , Eric A F Simões  2   3 , Armando Acevedo  4 , Jose M Novoa Pizarro  5 , Julie S Shepard  6 , Radha A Railkar  7 , Xin Cao  7 , Brian M Maas  7 , Xiaowei Zang  7 , Andrea Krick  7 , Brad Roadcap  7 , Kalpit A Vora  7 , Antonios O Aliprantis  7 , Andrew W Lee  7 , Anushua Sinha  7
Affiliations
Clinical Trial

A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants

Shabir A Madhi et al. J Infect Dis. .

Abstract

Background: Clesrovimab is an investigational monoclonal antibody with an extended half-life targeting site IV of the respiratory syncytial virus (RSV) fusion protein for the prevention of RSV disease in infants.

Methods: In this phase 1b/2a, double-blind study, 183 healthy preterm and full-term infants 2 weeks to 8 months of age were randomized 4:1 within 5 panels (preterm 20, 50, 75, or 100 mg; full-term 100 mg) to receive 1 dose of clesrovimab or placebo. The objectives were to evaluate safety, pharmacokinetics, serum neutralizing antibodies (SNA), and antidrug antibodies (ADA). The incidence of RSV-associated end points (medically attended lower respiratory tract infection, hospitalization, and acute respiratory infection) were also evaluated through 150 days postdose.

Results: The most common adverse event through day 14 was irritability; no treatment-related serious AEs were reported. Clesrovimab serum concentrations displayed a geometric mean apparent half-life of 44.9 days. Of participants receiving clesrovimab, 51 (36.7%) developed ADA with no apparent impact in pharmacokinetics. SNA titers increased in a dose-dependent manner at day 150. The incidences of RSV-associated end points were lower in infants treated with clesrovimab compared with placebo.

Conclusions: Clesrovimab was generally well tolerated and exhibited an extended half-life compared to typical IgG1 antibodies, supporting its ongoing development in late-stage trials. Clinical Trial Registration. NCT03524118.

Keywords: RSV; clesrovimab; monoclonal antibody.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. R. A. R., B. M. M., X. Z., A. K., B. R., and A. S. are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA and may hold stock in Merck & Co, Inc, Rahway, NJ, USA. X. C., A. O. A., and A. W. L. were employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA at the time of the study and may hold stock in Merck & Co, Inc, Rahway, NJ, USA. K. A. V. is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA may hold stock in Merck & Co, Inc, Rahway, NJ, USA and is named on a patent related to MK-1654. J. S. S. reports grants to her institution for serving as a principal investigator for the study. S. A. M. reports payment to his institution for participation in the clinical trial from Merck & Co, Inc, Rahway, NJ, USA; grants to his institution from BMGF, GSK, Pfizer, and Minervax; clinical trial grants to his institution from Novavax, Providence, Gritstone, and ImmunityBio; and participation in a data safety monitoring board for rotavirus vaccine at PATH and HIV monoclonal antibody at CAPRISA. E. A. F. S. reports grants or contracts from Astra Zeneca, Inc, Merck & Co, Inc, Rahway, NJ, USA, Pfizer, Inc, Sanofi Pasteur, Roche Pharmaceuticals, and Johnson and Johnson; consulting fees to his institution from Merck & Co, Inc, Rahway, NJ, USA, Pfizer, Inc, Sanofi Pasteur, Cidara Therapeutics, Adiago Therapeutics, Nuance Pharmaceuticals, Icosavax, Johnson and Johnson, and Sobi, Inc; payments or Honoria for lectures or presentations for Pfizer, Inc, and Astra Zeneca, support for attending meetings or travel from Astra Zeneca, and participation on a data safety monitoring board or advisory board for Abbvie, Inc, GlaxoSmithKline, and The Bill and Melinda Gates Foundation. J. M. N. P. reports grants or contracts from MSD as a principal investigator in MK-1654 clinical trials. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Participant disposition. *Two participants who were randomized to the clesrovimab 20-mg group actually received a 50-mg dose of clesrovimab and were included in the 50-mg clesrovimab group for safety, pharmacokinetic, serum neutralizing antibody, and antidrug antibodies analyses.
Figure 2.
Figure 2.
Observed mean clesrovimab serum concentration after a single dose in infants. Arithmetic mean serum concentrations are displayed for each group versus time in days after clesrovimab administration. Data are graphed at days 7, 14, 90, and 150; some points were staggered on x-axis to enable viewing. The majority of concentrations at day 365 were below the lower limit of quantification (0.5 μg/mL); group mean was not displayed at this time point. Data for the 20-mg time point at day 14 were calculated from 2 participants.
Figure 3.
Figure 3.
Serum-neutralizing antibody titers after a single dose of clesrovimab in infants. Respiratory syncytial virus serum concentration (50% inhibitory concentration) titers in natural log scale versus nominal time in days. Points represent the group arithmetic mean and error bars display the standard error. Data are graphed at days 1, 150, 365, and 545; points were staggered on x-axis to enable viewing. Number of participants included (n) for each group mean for days 1, 150, 365, and 545 (if applicable), respectively, are the following: 20-mg group = 5, 5, 2; 50-mg group = 32, 29, 12; 75-mg group = 39, 30, 17; 100-mg preterm group = 28, 22, 19, 20; 100-mg full-term group = 26, 27, 20, 21; and placebo group = 32, 29, 20, 11.
See this image and copyright information in PMC

References

    1. Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 2022; 399:2047–64. - PMC - PubMed
    1. Cantú-Flores K, Rivera-Alfaro G, Muñoz-Escalante JC, Noyola DE. Global distribution of respiratory syncytial virus A and B infections: a systematic review. Pathog Glob Health 2022; 116:398–409. - PMC - PubMed
    1. Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, et al. Respiratory syncytial virus seasonality: a global overview. J Infect Dis 2018; 217:1356–64. - PubMed
    1. Chuang YC, Lin KP, Wang LA, Yeh TK, Liu PY. The impact of the COVID-19 pandemic on respiratory syncytial virus infection: a narrative review. Infect Drug Resist 2023; 16:661–75. - PMC - PubMed
    1. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986; 140:543–6. - PubMed

Publication types

MeSH terms

Associated data